Key Insights

Highlights

Treatment Research

4 treatments under study, led by Capecitabine

Research Leaders

5 sponsors active, led by Bristol-Myers Squibb

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03585465Phase 1/2Terminated

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

Showing all 1 trials

Research Network

Common Treatments

  • Capecitabine1
  • Nivolumab1
  • Vinblastine1
  • Cyclophosphamide1

Active Sponsors

  • Bristol-Myers Squibb1
  • Centre Oscar Lambret1
  • CTD-CNO1
  • ECS-Progastrin SA1
  • Anticancer Fund, Belgium1

Top Investigators

Related Conditions

  • Childhood Solid Tumor1

Activity Timeline